Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
Performance
1 day | +4.67% | ||
1 month | +15.44% | ||
3 months | +42.94% | ||
6 months | +37.72% | ||
Current year | +35.54% | ||
1 year | +78.75% | ||
3 years | -54.16% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Biopharmaceuticals
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
+4.67% | -.--% | +35.54% | +78.75% | 1.31B | ||
+0.64% | -0.29% | -2.29% | -9.73% | 89.87B | ||
-0.27% | -2.80% | -3.95% | -7.36% | 37.57B | ||
+2.21% | +3.27% | -13.07% | -25.62% | 32.75B | ||
+1.70% | +0.12% | +63.05% | +59.18% | 26.47B | ||
+0.79% | -0.60% | -22.14% | -14.94% | 14.25B | ||
+0.86% | +0.84% | -7.96% | -6.05% | 12.99B | ||
+1.38% | +6.74% | -9.33% | +1.10% | 11.93B | ||
-0.09% | -1.18% | -46.33% | -30.73% | 10.84B | ||
+1.66% | +0.79% | +5.77% | +33.21% | 9.11B | ||
-0.14% | -1.95% | -17.66% | -3.30% | 7.32B | ||
+3.28% | -3.73% | +88.73% | +252.08% | 7.14B | ||
+2.42% | +2.59% | -6.12% | +12.95% | 7.1B | ||
-0.84% | +1.00% | -11.25% | +7.09% | 6.48B | ||
-0.14% | -0.56% | -8.40% | +7.02% | 6.45B | ||
+1.46% | +1.79% | -39.64% | -13.99% | 6.12B | ||
Average | +1.22% | +0.42% | +0.31% | +21.23% | ||
Weighted average by Cap. | +0.92% | -0.11% | +0.16% | +4.33% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2024 | +35.54% | ||
2023 | +8.59% | ||
2022 | -41.95% | ||
2021 | -53.04% | ||
2020 | +15.21% | ||
2019 | -17.59% |
- Stock Market
- Equities
- 2696 Stock
- Quotes Shanghai Henlius Biotech, Inc.